Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.180
-0.070 (-1.65%)
At close: Aug 29, 2025, 4:00 PM
4.240
+0.060 (1.44%)
After-hours: Aug 29, 2025, 6:48 PM EDT
Agenus Revenue
Agenus had revenue of $25.69M in the quarter ending June 30, 2025, with 9.28% growth. This brings the company's revenue in the last twelve months to $101.71M, down -36.29% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$101.71M
Revenue Growth
-36.29%
P/S Ratio
1.00
Revenue / Employee
$321,854
Employees
316
Market Cap
133.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AGEN News
- 4 days ago - Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript) - Seeking Alpha
- 6 days ago - Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight - Business Wire
- 13 days ago - Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 - Business Wire
- 21 days ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 4 weeks ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 5 weeks ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire
- 2 months ago - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 - Business Wire
- 2 months ago - Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology - Business Wire